Halcion (Triazolam)

Halcion (triazolam) is prescribed primarily for short‑term management of sleep difficulties. It is used when rapid sleep induction is needed and is generally limited to brief treatment periods to reduce the risk of dependence.

• Short‑term treatment of insomnia, especially difficulty falling asleep.
• Management of transient sleep disturbances associated with stress or travel.
• Adjunctive therapy for patients with acute sleep onset problems.
• Occasionally used in diagnostic sleep studies to standardize sleep onset timing.
• Not intended for chronic insomnia without specialist supervision.

Triazolam may cause a range of side effects that vary in frequency and severity. Patients should be aware of both common and less frequent but serious reactions.

Common

• Drowsiness or fatigue during the day.
• Light‑headedness or dizziness.
• Memory impairment, especially short‑term recall.
• Slurred speech or clumsiness.
• Headache.
• Gastrointestinal discomfort such as nausea.

Serious

• Severe allergic reactions (rash, swelling, difficulty breathing).
• Paradoxical agitation, aggression, or hallucinations.
• Respiratory depression, particularly when combined with other depressants.
• Significant dependence or withdrawal symptoms upon discontinuation.
• Mood changes including depression or suicidal thoughts.

Before starting Halcion, several safety considerations should be reviewed to minimize risks. These precautions are especially important for vulnerable populations.

• Use only for the shortest duration necessary; prolonged use increases dependence risk.
• Avoid use in pregnancy (Category D) due to potential fetal harm.
• Caution in elderly patients because of heightened sensitivity to sedation and falls.
• Do not operate heavy machinery or drive until you know how the medication affects you.
• Patients with a history of substance abuse should be evaluated carefully.
• Inform your healthcare provider of any liver or kidney impairment.

Triazolam can interact with other substances, altering its effectiveness or safety profile. Some combinations should be avoided, while others require careful monitoring.

Avoid

• Other central nervous system depressants (e.g., alcohol, opioids, barbiturates, antihistamines).
• Strong CYP3A4 inhibitors such as ketoconazole, itraconazole, or ritonavir, which can increase triazolam levels.
• Certain antidepressants (e.g., fluoxetine, fluvoxamine) that may raise plasma concentrations.

Use with caution

• Other benzodiazepines or sedative‑hypnotics.
• Anticonvulsants that induce CYP3A4 (e.g., carbamazepine, phenytoin) may reduce efficacy.
• Herbal supplements like St. John’s wort that affect liver enzymes.
• Medications that prolong QT interval; monitor cardiac status if combined.